[Federal Register Volume 69, Number 157 (Monday, August 16, 2004)]
[Notices]
[Page 50391]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-18622]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Diagnostic Tool for Diagnosing Benign Versus Malignant Thyroid Lesions

Steven Libutti et al. (NCI)
U.S. Provisional Application No. 60/560,900 filed 09 Apr 2004 (DHHS 
Reference No. E-124-2004/0-US-01)
Licensing Contact: Mojdeh Bahar; 301/435-2950; [email protected].

    The present invention is directed to the use of genes 
differentially expressed in benign and malignant thyroid lesions for 
the diagnosis and staging of thyroid cancer. The invention allows for 
the analysis of RNA isolated from tissues using gene expression 
profiling. The invention has identified a group of genes which can be 
used as a diagnostic predictor model for differentiating benign versus 
malignant thyroid tissue using microarray or quantitative RT-PCR.

Pharmacodynamic Assay

Eun Joo Chung and Jane Trepel (NCI)
U.S. Provisional Application No. 60/548,894 filed 27 Feb 2004 (DHHS 
Reference No. E-094-2004/0-US-01)
Licensing Contact: Mojdeh Bahar; 301/435-2950; [email protected].

    This invention is a rapid, simple, sensitive flow cytometric assay 
for the pharmacodynamic analysis of histone deacetylase inhibitors in 
clinical development as novel anti-cancer agents. The assay can be 
performed on 50 microliters of whole blood, the equivalent of a finger 
stick. The assay can quantify simultaneously the effects of multiple 
classes of drug and thus be used for pharmacodynamic analysis of HDAC 
inhibitors in combination therapy.

Adduct Compounds of Pyrrolobenzodiazepinones, Compositions Comprising 
the Same and Methods Related Thereto

Paul S. Liu (NCI), Gregory Turner, Babu R. Vishnuvajjala (NCI), David 
Thurston (EM), and Philip W. Howard (EM)
U.S. Provisional Application No. 60/513,751 filed 22 Oct 2003 (DHHS 
Reference No. E-007-2004/0-US-01)
Licensing Contact: Brenda Hefti; 301/435-4632; [email protected].

    This invention is a small molecule that has potential as a cancer 
therapeutic, termed SJG-136. It is a dimeric synthetic analog of the 
pyrrolobenzodiazepine family of anti-tumor antibiotics derived from 
various Streptomyces species. SJG-136 has shown significant 
cytotoxicity and antitumor activity in vitro and in vivo. The 
particular compositions disclosed in the present application represent 
new structures that were not claimed previously.

    Dated: August 6, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 04-18622 Filed 8-13-04; 8:45 am]
BILLING CODE 4140-01-P